Global epidemiology of tuberculosis

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 1, 2013, Pages 3-16

  Glaziou, Philippe ^a   Falzon, Dennis ^a   Floyd, Katherine ^a   Raviglione, Mario ^a  

^a UNAIDS   (Switzerland)

Author keywords

burden; epidemiology; incidence; mortality; prevalence; tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC THERAPY; ARTICLE; HUMAN; INCIDENCE; INFECTION PREVENTION; LUNG TUBERCULOSIS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; INCIDENCE; PREVALENCE; TUBERCULOSIS; WORLD HEALTH;

EID: 84874397562     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1333467     Document Type: Article

References (98)

1. WHO Global tuberculosis report 2012. Geneva, Switzerland WHO: 2012
2. WHO, ed. The Global Burden of Disease: 2004 Update. Geneva, Switzerland World Health Organization: 2008
3. Lopez A. D., Mathers C. D., Ezzati M., Jamison D. T., Murray C. J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet: 2006; 367 9524 1747 1757 (Pubitemid 43767064)
4. Miller T. L., McNabb S. J., Hilsenrath P., Pasipanodya J., Weis S. E. Personal and societal health quality lost to tuberculosis. PLoS ONE: 2009; 4 4 e5080
5. Zumla A., Mwaba P., Huggett J., Kapata N., Chanda D., Grange J. Reflections on the white plague. Lancet Infect Dis: 2009; 9 3 197 202
6. Lienhardt C., Glaziou P., Uplekar M., Lönnroth K., Getahun H., Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol: 2012; 10 6 407 416
7. Murray C. J., DeJonghe E., Chum H. J., Nyangulu D. S., Salomao A., Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet: 1991; 338 8778 1305 1308
8. Dye C., Floyd K. Tuberculosis. In: Jamison D. T., Breman J. G., Measham A. R., et al, eds. Disease Control Priorities in Developing Countries. Washington, DC Oxford University Press: 2006; 289 309
9. Dye C., Bassili A., Bierrenbach A. L., et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis: 2008; 8 4 233 243
10. Raviglione M. C., Uplekar M. W. WHO's new Stop TB Strategy. Lancet: 2006; 367 9514 952 955
11. Korenromp E. L., Glaziou P., Fitzpatrick C., et al. Implementing the global plan to stop TB, 2011-2015-optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS ONE: 2012; 7 6 e38816
12. Raviglione M. C. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis: 2006; 10 3 238 239
13. Raviglione M. C. The new Stop TB Strategy and the Global Plan to Stop TB, 2006-2015. Bull World Health Organ: 2007; 85 5 327 (Pubitemid 46718355)
14. Van Hest N. A., Story A., Grant A. D., Antoine D., Crofts J. P., Watson J. M. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999-2002. Epidemiol Infec: 2008; 136 12 1606 1616
15. Bierrenbach A. L., Stevens A. P., Gomes A. B., et al. [Impact on tuberculosis incidence rates of removal of repeat notification records.]. Rev Saude Publica: 2007; 41 01 67 76
16. Dye C., Ottmani S., Laasri L., Bencheikh N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int J Tuberc Lung Dis: 2007; 11 11 1225 1231 (Pubitemid 350146305)
17. Mansoer J. SS, Scheele S., Floyd K., Dye C., Sitienei J., Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ: 2009; 87 3 186 192, 192A-192B
18. Botha E., den Boon S., Lawrence K. A., et al. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis: 2008; 12 8 936 941
19. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA: 1999; 282 7 677 686
20. Uplekar M., Pathania V., Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet: 2001; 358 9285 912 916 (Pubitemid 32900580)
21. Meintjes G., Schoeman H., Morroni C., Wilson D., Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis: 2008; 8 72
22. Véron L. J., Blanc L. J., Suchi M., Raviglione M. C. DOTS expansion: will we reach the 2005 targets? Int J Tuberc Lung Dis: 2004; 8 1 139 146 (Pubitemid 38120718)
23. Baussano I., Bugiani M., Gregori D., et al. Undetected burden of tuberculosis in a low-prevalence area. Int J Tuberc Lung Dis: 2006; 10 4 415 421
24. Borgdorff M. W., Glynn J. R., Vynnycky E. Using capture-recapture methods to study recent transmission of tuberculosis. Int J Epidemiol: 2004; 33 4 905 906, author reply 907
25. Cailhol J., Che D., Jarlier V., Decludt B., Robert J. Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. Int J Tuberc Lung Dis: 2005; 9 7 803 808 (Pubitemid 41139135)
26. Crofts J. P., Pebody R., Grant A., Watson J. M., Abubakar I. Estimating tuberculosis case mortality in England and Wales, 2001-2002. Int J Tuberc Lung Dis: 2008; 12 3 308 313 (Pubitemid 351361902)
27. WHO, ed. Tuberculosis Prevalence Surveys: A Handbook. Geneva, Switzerland WHO: 2011
28. Glaziou P., van der Werf M. J., Onozaki I., et al. Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis: 2008; 12 9 1003 1008
29. Soemantri S., Senewe F. P., Tjandrarini D. H., et al. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis: 2007; 11 4 398 404 (Pubitemid 46595769)
30. Dye C., Fengzeng Z., Scheele S., Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol: 2000; 29 3 558 564 (Pubitemid 30447263)
31. Tupasi T. E., Radhakrishna S., Rivera A. B., et al. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis: 1999; 3 6 471 477 (Pubitemid 29260158)
32. Hong Y. P., Kim S. J., Lew W. J., Lee E. K., Han Y. C. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis: 1998; 2 1 27 36 (Pubitemid 28108939)
33. Korenromp E. L., Bierrenbach A. L., Williams B. G., Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis: 2009; 13 3 283 303
34. WHO Guidelines for Surveillance of Drug Resistance in Tuberculosis. Geneva, Switzerland WHO: 2009
35. Riley R. L. The contagiosity of tuberculosis. Schweiz Med Wochenschr: 1983; 113 3 75 79
36. WHO Tuberculosis Fact Sheet. Geneva, Switzerland WHO: 2012
37. Borgdorff M. W., Sebek M., Geskus R. B., Kremer K., Kalisvaart N., van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol: 2011; 40 4 964 970
38. Vynnycky E., Fine P. E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol: 2000; 152 3 247 263 (Pubitemid 30640248)
39. Tiemersma E. W., van der Werf M. J., Borgdorff M. W., Williams B. G., Nagelkerke N. J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE: 2011; 6 4 e17601
40. Straetemans M., Glaziou P., Bierrenbach A. L., Sismanidis C., van der Werf M. J. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS ONE: 2011; 6 6 e20755
41. Shilova M. V., Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci: 2001; 356 1411 1069 1075 (Pubitemid 32696251)
42. Glaziou P., Floyd K., Korenromp E. L., et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ: 2011; 89 8 573 582
43. Straetemans M., Bierrenbach A. L., Nagelkerke N., Glaziou P., van der Werf M. J. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE: 2010; 5 12 e15241
44. Williams B. G., Granich R., De Cock K. M., Glaziou P., Sharma A., Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA: 2010; 107 45 19485 19489
45. Corbett E. L., Charalambous S., Moloi V. M., et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med: 2004; 170 6 673 679 (Pubitemid 39202210)
46. Ottmani S. E., Uplekar M. W. Gender and TB: pointers from routine records and reports. Int J Tuberc Lung Dis: 2008; 12 7 827 828 (Pubitemid 351976719)
47. Thorson A., Long N. H., Larsson L. O. Chest X-ray findings in relation to gender and symptoms: a study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis: 2007; 39 1 33 37 (Pubitemid 46277145)
48. Borgdorff M. W., Nagelkerke N. J., Dye C., Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis: 2000; 4 2 123 132 (Pubitemid 30123645)
49. Connolly M., Nunn P. Women and tuberculosis. World Health Stat Q: 1996; 49 2 115 119 (Pubitemid 27094703)
50. Somma D., Thomas B. E., Karim F., et al. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis: 2008; 12 7 856 866 (Pubitemid 351976724)
51. WHO Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015. WHO Progress Report 2011. Geneva, Switzerland WHO: 2011;. Report No.: WHO/HTM/TB/2011.3
52. Zignol M., van Gemert W., Falzon D., et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ: 2012; 90 2 111 119D
53. WHO WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide. Geneva, Switzerland WHO: 2006;. Available at: www.who.int/mediacentre/news/ notes/2006/np29/. Accessed January 18, 2013
54. Velayati A. A., Masjedi M. R., Farnia P., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest: 2009; 136 2 420 425
55. Migliori G. B., De Iaco G., Besozzi G., Centis R., Cirillo D. M. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill: 2007; 12 5 E070517.1
56. Udwadia Z. F., Amale R. A., Ajbani K. K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis: 2012; 54 4 579 581
57. WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update. Geneva, Switzerland WHO: 2011
58. Meyer-Rath G., Schnippel K., Long L., et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE: 2012; 7 5 e36966
59. Evans C. A. GeneXpert-a game-changer for tuberculosis control? PLoS Med: 2011; 8 7 e1001064
60. Dye C., Garnett G. P., Sleeman K., Williams B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet: 1998; 352 9144 1886 1891 (Pubitemid 28561249)
61. Dye C., Watt C. J., Bleed D. M., Hosseini S. M., Raviglione M. C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA: 2005; 293 22 2767 2775 (Pubitemid 40965089)
62. Lönnroth K., Castro K. G., Chakaya J. M., et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet: 2010; 375 9728 1814 1829
63. Raviglione M., Marais B., Floyd K., et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet: 2012; 379 9829 1902 1913
64. Lönnroth K., Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med: 2008; 29 5 481 491
65. Raviglione M. C., Sudre P., Rieder H. L., Spinaci S., Kochi A. Secular trends of tuberculosis in western Europe. Bull World Health Organ: 1993; 71 3-4 297 306 (Pubitemid 23200072)
66. Grzybowski S., Styblo K., Dorken E. Tuberculosis in Eskimos. Tubercle: 1976; 57 4, Suppl S1 S58
67. WHO Health Financing for Universal Coverage. Geneva, Switzerland WHO: 2012
68. Dye C., Williams B. G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface: 2008; 5 23 653 662 (Pubitemid 351589747)
69. Sterling T. R. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med: 2008; 29 5 532 541
70. Woldehanna S., Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev: 2004; 1 CD000171
71. Churchyard G. J., Scano F., Grant A. D., Chaisson R. E. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis: 2007; 196 01 S52 S62 (Pubitemid 47206085)
72. Harries A. D., Zachariah R., Lawn S. D. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis: 2009; 13 1 6 16
73. Grimwade K., Sturm A. W., Nunn A. J., Mbatha D., Zungu D., Gilks C. F. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS: 2005; 19 2 163 168 (Pubitemid 40409534)
74. WHO and UNAIDS issue new guidance on HIV testing and counselling in health facilities, 2007. http://www.who.int/mediacentre/news/releases/2007/pr24/ en/index.html. Accessed January 12, 2013
75. Bock N. N., Jensen P. A., Miller B., Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis: 2007; 196 01 S108 S113 (Pubitemid 47206089)
76. Wells C. D., Cegielski J. P., Nelson L. J., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis: 2007; 196 01 S86 S107 (Pubitemid 47206088)
77. WHO, ed. Global Tuberculosis Control 2009: Surveillance, Planning, Financing. Geneva, Switzerland WHO: 2009
78. Shah N. S., Wright A., Bai G. H., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis: 2007; 13 3 380 387 (Pubitemid 46348124)
79. Migliori G. B., Loddenkemper R., Blasi F., Raviglione M. C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "scienceo" enough to tackle the epidemic? EurRespir J: 2007; 29 3 423 427 (Pubitemid 46372084)
80. Manissero D., Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill: 2006; 11 11 E061103.1
81. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis: 2006; 10 11 1185 1187
82. Raviglione M. C., Smith I. M. XDR tuberculosis-implications for global public health. N Engl J Med: 2007; 356 7 656 659
83. Hopewell P. C., Pai M., Maher D., Uplekar M., Raviglione M. C. International standards for tuberculosis care. Lancet Infect Dis: 2006; 6 11 710 725 (Pubitemid 44740086)
84. Lönnroth K., Uplekar M., Arora V. K., et al. Public-private mix for DOTS implementation: what makes it work? Bull World Health Organ: 2004; 82 8 580 586 (Pubitemid 39108147)
85. Ambe G., Lönnroth K., Dholakia Y., et al. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis: 2005; 9 5 562 568 (Pubitemid 40646844)
86. Lönnroth K., Uplekar M. Invest in breaking the barriers of public-private collaboration for improved tuberculosis care. Bull World Health Organ: 2005; 83 7 558 559 (Pubitemid 41003334)
87. Floyd K., Arora V. K., Murthy K. J., et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ: 2006; 84 6 437 445 (Pubitemid 43845443)
88. Pantoja A., Floyd K., Unnikrishnan K. P., et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part 1: Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis: 2009; 13 6 698 704
89. Pai M., O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med: 2008; 29 5 560 568
90. Ly L. H., McMurray D. N. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines: 2008; 7 5 635 650 (Pubitemid 351881346)
91. Lienhardt C., Raviglione M., Spigelman M., et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis: 2012; 205 02 S241 S249
92. Nicolau I., Ling D., Tian L., Lienhardt C., Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS ONE: 2012; 7 7 e42479
93. Lönnroth K., Jaramillo E., Williams B. G., Dye C., Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med: 2009; 68 12 2240 2246
94. Moreno-Serra R., Smith P. C. Does progress towards universal health coverage improve population health? Lancet: 2012; 380 9845 917 923
95. Squire S. B., Obasi A., Nhlema-Simwaka B. The Global Plan to Stop TB: a unique opportunity to address poverty and the Millennium Development Goals. Lancet: 2006; 367 9514 955 957
96. Raviglione M., Zumla A., Marais B., Horton R., Motsoaledi A. A sustainable agenda for tuberculosis control and research. Lancet: 2012; 379 9821 1077 1078
97. World Health Organization Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland WHO: 2007
98. Raviglione M. C., Uplekar M. W. WHO's new Stop TB Strategy. Lancet: 2006; 367 9514 952 955